Dec 14, 2021 / 01:00PM GMT
Tianyi Zhang - I-Mab - Executive Director of IR
Good day, ladies and gentlemen. Thank you for standing by. This is Tianyi Zhang, IR Head of I-Mab Biopharma. Thank you for joining the conference call today.
Yesterday, I-Mab presented clinical data of lemzoparlimab in combination with rituximab in NHL patients at ASH meeting. Today's conference, we will have the management team to give you more insights of the clinical data and the future development plan. Joining me today on the call from I-Mab's senior management team include Dr. Jingwu Zhang, Founder and Chairman of I-Mab; Dr. Joan Shen, CEO of I-Mab; I-Mab; and Mr. John Long, Chief Financial Officer of I-Mab.
Today's conference call will be divided into 2 parts. First, the management team will give an in-depth overview of the clinical data, and it will be followed by a Q&A session.
Now I'd like to turn the call to Dr. Jingwu Zhang, Founder and Chairman of I-Mab, to share with you more details about the clinical trial.
Jingwu Zhang Zang - I-Mab - Founder & Chairman
Thank you
I-Mab Most Recent Clinical Data Update Conference Call -- English Session Transcript
Dec 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers